Marinomed Biotech AG (VIE:MARI)
Austria · Delayed Price · Currency is EUR 11.00
+0.20 (1.85%)
Jun 5, 2026, 5:37 PM CET
Marinomed Biotech AG Company Description
Marinomed Biotech AG operates as a biopharmaceutical company in Austria, other European countries, and internationally.
Its lead products include Budesolv for the treatment of allergic rhinitis in late-stage clinical development; and Tacrosolv for the treatment of inflammatory eye diseases in Phase II clinical studies.
The company also develops Satiasolv for pain immune reactions in the preclinical development phase. In addition, it provides Solv4U for formulation development and biopharmaceutical testing services.
The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017.
Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.
Marinomed Biotech AG
| Country | Austria |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Andreas Grassauer |
Contact Details
Address: Hovengasse 25 Korneuburg, Vienna 2100 Austria | |
| Phone | 43 2262 90300 |
| Website | marinomed.com |
Stock Details
| Ticker Symbol | MARI |
| Exchange | Vienna Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | ATMARINOMED6 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Andreas Grassauer Ph.D. | Co-Founder, Chairman of Management Board and Chief Executive Officer |
| Eva Prieschl-Grassauer Ph.D. | Co-Founder, Vice Chairwoman of Management Board and Chief Scientific Officer |
| Gabriele Ram | Chief Financial Officer and Member of Management Board |
| Stephanie Kniep | Head of Investor Relations |